Table 2 Characteristics of the population (n = 241)
From: Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer
Mean ± SD (Min-max) | ||
|---|---|---|
Age (years) | 66 ± 7 (43 – 80) | |
Pre-treatment PSA (ng/mL) | 6.6 ± 2.2 (1.2 - 12.6) | |
Pre-treatment index of prostatic symptom score (IPSS) | 4.0 ± 2.8 (0 – 15) | |
Pre-treatment prostate volume (cm 3 ) | 36.3 ± 9.7 (14 – 67) | |
N (%) | ||
Gleason score | None | 10 (4.2) |
< 6 | 43 (17.8) | |
6 | 146 (60.6) | |
7 | 42 (17.4) | |
Stage | T1C | 147 (61) |
T2A | 89 (37) | |
T2B | 5 (2) | |
Diabetes | 19 (8) | |
Vascular disorders | 46 (19) | |
Obesity (Body mass Index > 2.8) | 22 (9) | |
Contraindication to surgery | 25 (10) | |
Neoadjuvant hormonal therapy* | 63 (26) | |